ArticleMaterials today. Bio2026

Feasibility of combining JAK1 gene editing via CRISPR-CasRx with EGCG-lactoferrin nanoparticle therapy in a microneedle-based platform for atopic dermatitis.

Huanqing Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.